Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Breach of Fiduciary Duty—New Legal Approach for Plaintiffs

December 1, 1997
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 12
Volume 6
Issue 12

SANTA MONICA, Calif-The managed care system of delivering medical benefits has not only altered the way physicians provide care but also drastically changed the landscape in health care law, said Mark O. Hiepler, Esq, a plaintiff attorney and partner in the firm of Hiepler & Hiepler, Oxnard, California.

SANTA MONICA, Calif—The managed care system of delivering medical benefits has not only altered the way physicians provide care but also drastically changed the landscape in health care law, said Mark O. Hiepler, Esq, a plaintiff attorney and partner in the firm of Hiepler & Hiepler, Oxnard, California.

Plaintiff attorneys are asking whether the large profits being made by managed care organizations are coming at the expense of patient care, he said at a seminar sponsored by the Defense Research Institute, Inc., Chicago.

Mr. Hiepler’s firm is developing the theory of breach of fiduciary duty as a legal cause of action against physicians and managed care organizations. The doctor-patient relationship epitomizes a fiduciary relationship, he said, because patients must rely on their doctor’s fidelity and integrity to put their medical needs ahead of the doctor’s financial interests.

Shift From Denying Payment to Denying Treatment

The most significant shift in the health care litigation environment stems from the change from retrospective to prospective claim review, Mark Hiepler said.

With retrospective review, the doctor and the patient made a treatment decision, the patient got the treatment, and if there was a lawsuit, it was usually over who would cover the treatment costs.

These cases were, in essence, business litigation cases over paying for the referral to a specialist or university hospital, or for a high-tech procedure. Mr. Hiepler noted that usually the insurer would end up paying for the treatment.

Now, with prospective review, “gatekeeper” physicians and utilization review coordinators may keep a patient from receiving more specialized care and treatments. “You now have two components to damages: the cost of the care, and the human costs due to delay or denial of treatment,” he said.

Typically, medical malpractice cases only examine whether the physician provided medical treatment that was within the standard of care for the local community. The physician’s motivation in deciding on a particular course of treatment is considered irrelevant. However, in a breach of fiduciary duty case, the physician’s motivation, especially with regard to financial concerns, takes center stage.

“In every one of these fiduciary duty trials, we’re going to cite the Hippocratic oath: You’re to do no harm, and you’re to put the patient’s interest first and foremost,” Mr. Hiepler said.

The physician/managed care organization contract is an important driving force in such trials, he said. Even though defense attorneys have used many legal maneuvers to prevent him from obtaining contracts, he said that he had succeeded in having the contract admitted into evidence in all cases where he felt it was necessary.

“We’ve had it admitted in cases tried in six counties throughout California,” he said. Once a plaintiff attorney has the applicable contract, it is often not difficult to find clauses that, when presented to the jury, tend to cast an unfavorable light on the defendant physician.

“You look at how the compensation is fixed. Are there incentives not to treat, not to refer, not to hospitalize, or not to continue to hospitalize, not to prescribe, not to diagnose?” he asked.

How it Looks to the Jury

Mr. Hiepler pointed out that when such financial incentives in a contract are brought before a jury, the effect on them is pronounced. “It looks as if the doctor is in a conspiracy with the plan to keep these incentives as their dirty little secret. Physicians know how it works. These incentives make the difference in whether their practice survives or goes under,” he said.

Breach of fiduciary duty can be argued when “you can expose the contract and the pattern of conduct that shows an incentive not to treat,” Mr. Hiepler said. He noted that in a medical malpractice case, the plaintiff attorney must prove malpractice and show causation of significant damages. But, theoretically, that would not be necessary with breach of fiduciary duty as a cause of action.

Mr. Hiepler has also noticed a change in jurors’ perceptions of the doctor-patient relationship. Even though he has tried such cases in the most conservative courthouses in California, he has found that when the financial incentives in a physician’s contract with a managed care organization are exposed, jurors are alarmed to see how the compensation system is set up.

Especially in denial of medical treatment cases, the jury expects that doctors should act as a patient advocate with the managed care plan, fighting to get the necessary medical treatment. “Yet we’re getting into the category where the doctor is seen as an adversary of the patient,” he said.

An Unlikely Alliance

In what he deemed an unlikely alliance, Mr. Hiepler noted that some physicians are interested in joining with plaintiff attorneys to try to change the managed care system. When he speaks at medical conventions, he said, physicians often approach him to ask if they can help with the lawsuits he brings against managed care organizations, and many of these physicians are considered top experts in their fields.

“They want to be part of the reform process,” he said. “We ask them to look at potential cases long before we ever file a complaint.” He explained that his firm receives about 125 to 150 telephone calls a month regarding potential cases against managed care organizations, and since the litigation process is long and costly, cases need to be analyzed for their appropriateness and probability of success.

Pitfalls of Capitation

Mr. Hiepler expressed concerns about the pressures of capitation on physicians. “Doctors have had to become insurance companies. They have to assume the risk, hoping that the patient population is actuarially sound, usually with little evidence. We’re seeing contracts with primary care physicians at $5 or less per patient per month,” he said.

Some physicians sign these contracts without realistically evaluating the terms because they’re afraid of losing the managed care organization’s patients. Many, however, may want an incentive contract that gives them the discretion to treat or to deny, he said. But he warned the audience that such contracts can come back to haunt physicians, especially when they are involved in a jury trial.

He said that in a trial the plaintiff attorneys will scrutinize any financial incentives in the contract, such as risk pools. For example, a small percentage of each payment premium may be accumulated into a pool used to pay for referrals to specialists outside the medical group. At the end of the year, if any funds are left, they are split between the managed care company and the physician. “This can be seen by juries as an incentive not to refer,” he said.

Also problematic for physicians, he said, are overutilization and termination clauses. Such a clause might read: “Overutilization of the system by physicians shall be grounds for termination of the contract. Overutilization determinations are at the sole discretion of the managed care organization.”

He warns that these clauses are setting physicians up for a failure to refer. “This type of clause has the tragic potential to hang a doctor, even one who may not have intended to do anything unethical,” Mr. Hiepler said. He noted that such agreements seem to go against our basic American principles, since “you get paid for doing nothing, and you lose money when you do more.”

Articles in this issue

Team-Based Approach to Managed Specialty Care
Children’s Art Project at M.D. Anderson
Office of Cancer Survivorship Grants Awards for First 20 Studies
Laparoscopic Colectomy May Prove Equivalent to Open Surgery
Advice on Negotiating BMT Service Contracts
Komen Debuts New Websites on Breast Cancer
‘MDs Too Often Fail to Give Adequate Analgesic Doses’
Breach of Fiduciary Duty-How to Defend Against It
Survivors Help Women Deal With Breast Cancer Diagnosis
University of Utah’s Huntsman Cancer Institute Joins NCCN
Few Absolute Contraindications to Breast Conservation
‘Electronic Inhaler’ for Rapid Delivery of Morphine in Cancer Pain
Life-Saving Oral Cancer Exam Takes Only a Minute
Brachytherapy Offers Early-Stage Prostate Cancer Patients High QOL
Patients Sought for New Trial of Adoptive Immunotherapy

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
2 experts in this video
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
2 experts in this video
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
Related Content

TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC

TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC

Radhika Appaya;Mario Campone;Louise Emmett;Dejan Juric;Debasish Tripathy;Sonia Pernas;Monica Zuradelli;Kevin Perraud;Aleix Prat
June 21st 2025
Article


PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
June 19th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.


Data from the phase 3 GEMSTONE-302 trial support sugemalimab plus chemotherapy as a frontline treatment option in metastatic non–small cell lung cancer.

Sugemalimab/Chemotherapy Improves Long-Term Survival in Metastatic NSCLC

Russ Conroy
June 20th 2025
Article

Data from the phase 3 GEMSTONE-302 trial support sugemalimab plus chemotherapy as a frontline treatment option in metastatic non–small cell lung cancer.


Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
June 16th 2025
Podcast

Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.


Aspirin Does Not Limit Recurrence, Improve Survival in CRC Liver Metastases

Aspirin Does Not Limit Recurrence, Improve Survival in CRC Liver Metastases

Tim Cortese
June 20th 2025
Article

Aspirin led to a median disease-free survival of 1.16 years vs 1.35 years with placebo in patients with colorectal cancer liver metastases.


Results from the phase 3 DeFi trial showed superior progression-free survival with nirogacestat vs placebo in patients with progressing desmoid tumors.

Nirogacestat Receives Positive Opinion from CHMP in Desmoid Tumors

Tim Cortese
June 20th 2025
Article

Results from the phase 3 DeFi trial showed superior progression-free survival with nirogacestat vs placebo in patients with progressing desmoid tumors.

Related Content

TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC

TPS 25 Phase 1/2 Study of the Novel Radioligand Therapy [177Lu]Lu-NeoB Plus Capecitabine in Patients With ER+/HER2− Advanced Breast Cancer (ABC) With GRPR Expression After Progression on Prior Endocrine Therapy Plus a CDK4/6 Inhibitor for ABC

Radhika Appaya;Mario Campone;Louise Emmett;Dejan Juric;Debasish Tripathy;Sonia Pernas;Monica Zuradelli;Kevin Perraud;Aleix Prat
June 21st 2025
Article


PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

PODCAST: ASCO 2025 Debrief: Key Updates in Genitourinary Cancer Management

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
June 19th 2025
Podcast

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss abstracts from the 2025 ASCO Annual Meeting that may impact genitourinary cancer care.


Data from the phase 3 GEMSTONE-302 trial support sugemalimab plus chemotherapy as a frontline treatment option in metastatic non–small cell lung cancer.

Sugemalimab/Chemotherapy Improves Long-Term Survival in Metastatic NSCLC

Russ Conroy
June 20th 2025
Article

Data from the phase 3 GEMSTONE-302 trial support sugemalimab plus chemotherapy as a frontline treatment option in metastatic non–small cell lung cancer.


Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.

Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC

Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
June 16th 2025
Podcast

Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.


Aspirin Does Not Limit Recurrence, Improve Survival in CRC Liver Metastases

Aspirin Does Not Limit Recurrence, Improve Survival in CRC Liver Metastases

Tim Cortese
June 20th 2025
Article

Aspirin led to a median disease-free survival of 1.16 years vs 1.35 years with placebo in patients with colorectal cancer liver metastases.


Results from the phase 3 DeFi trial showed superior progression-free survival with nirogacestat vs placebo in patients with progressing desmoid tumors.

Nirogacestat Receives Positive Opinion from CHMP in Desmoid Tumors

Tim Cortese
June 20th 2025
Article

Results from the phase 3 DeFi trial showed superior progression-free survival with nirogacestat vs placebo in patients with progressing desmoid tumors.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.